Adrian Newman‐Tancredi

NLX-101, a 5-HT1A receptor biased agonist, improves multiple behavioral and cognitive deficits in FMR1 KO2 mice, showing dose-dependent effects.

This study evaluates the analgesic effects of NLX-204, a 5-HT1A receptor agonist, in rat models of osteoarthritis and post-operative pain, showing dose-dependent pain relief compared to morphine.

This study shows NLX-112 protects against MPTP-induced dopaminergic neuron loss in mice by reducing microgliosis, increasing GDNF, and improving locomotor activity.

This study tests the 5-HT1A agonist NLX-112 in SCA3 mice, finding it improves motor performance in a swimming test.

This study evaluates NLX-112, a 5-HT1A receptor agonist, in a mouse model of SCA3, showing improved motor function and neuroprotection when administered pre-symptomatically.